MedTrace Logo

Multivessel TALENT

NCT04390672 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1550

Last updated 2026-02-27

No results posted yet for this study

Summary

Multivessel TALENT is a prospective, randomized, multi-center study comparing clinical outcomes between SUPRAFLEX Cruz and SYNERGY in approximately 1550 patients with de-novo three vessel disease undergoing percutaneous coronary intervention (PCI). Patients will be treated according to "state of art PCI"; not only treatment strategies based on the latest ESC guideline, such as SYNTAX Score II recommendation, Heart Team discussion, post-procedure intravascular imaging optimization, cholesterol reduction by statin or PCSK-9 inhibitor, but also exploratory treatment strategies based on the latest evidence, such as physiological assessment using quantitative flow ratio and prasugrel monotherapy following 1-month dual antiplatelet therapy after PCI.

Conditions

Interventions

DEVICE

SUPRAFLEX Cruz

Percutaneous Coronary Intervention for multivessel disease

DEVICE

SYNERGY

Percutaneous Coronary Intervention for multivessel disease

Sponsors & Collaborators

  • National University of Ireland, Galway, Ireland

    lead OTHER

Principal Investigators

  • Patrick W. Serruys, MD, PhD · National University of Ireland, Galway

  • William Wijns, MD, PhD · National University of Ireland, Galway

  • Yoshinobu Onuma, MD, PhD · National University of Ireland, Galway

  • Helge Moellmann, MD · St. Johannes Hospital

  • Manel Sabate, MD, PhD · Hospital Clínic of Barcelona

  • Azfar Zaman, MD · Freeman Hospital and Newcastle University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2025-09-23
Completion
2026-09-30

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390672 on ClinicalTrials.gov